Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06095570
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-09-30
Brief Title:
The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation
Sponsor:
The Second Affiliated Hospital of Hainan Medical University
Organization:
The Second Affiliated Hospital of Hainan Medical University
Study Overview
Official Title:
The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Preliminary studies have illuminated the promising nature of ciprofol indicating its enhanced safety spectrum superior potency and a diminished likelihood of experiencing injection-related discomfort Venturing deeper this research embarked on an ambitious quest to measure the 95 effective volume of ciprofol for induction of general anesthesia by a modified sequential method and juxtapose the 95 effective volume dosage of ciprofol against a corresponding dose of remimazolam during the initiation of general anesthesia The study delved into diverse anesthetic protocols meticulously scrutinizing the safety and efficacy credentials of ciprofol The ultimate vision was to pave a robust foundation for the sophisticated and judicious utilization of ciprofol in clinical landscapes
Detailed Description:
During general anesthesia induction tracheal intubation is a significant procedure that can cause cardiovascular fluctuations due to the stimulation of tracheal receptors This can lead to complications such as imbalances in vital organ oxygen supply especially in patients with cardiovascular and cerebrovascular disorders potentially resulting in cardiac arrest As the demand for anesthetics rises in clinical settings some due to extreme side effects have been phased out reducing the available options
Propofol a common anesthetic is effective and quick but has drawbacks like injection pain and risks associated with long-term use In contrast ciprofol a new class I intravenous anesthetic is emerging as a potentially better alternative Early research indicates that ciprofol might have a broader safety margin than propofol and offers benefits like rapid recovery and lower chances of injection pain
Exhaustive studies on the precise dosage of ciprofol for surgical applications are scarce and comparisons between ciprofol and remimazolam are rarely reported in the literature This research aims to bridge this knowledge gap exploring the best dosage for tracheal intubation sedation and ensuring patients get the most effective and safest anesthetic care
Propofol a common anesthetic is effective and quick but has drawbacks like injection pain and risks associated with long-term use In contrast ciprofol a new class I intravenous anesthetic is emerging as a potentially better alternative Early research indicates that ciprofol might have a broader safety margin than propofol and offers benefits like rapid recovery and lower chances of injection pain
Exhaustive studies on the precise dosage of ciprofol for surgical applications are scarce and comparisons between ciprofol and remimazolam are rarely reported in the literature This research aims to bridge this knowledge gap exploring the best dosage for tracheal intubation sedation and ensuring patients get the most effective and safest anesthetic care
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None